MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Initial 24-hours Levodopa Carbidopa Intestinal Gel initiation in advanced Parkinson’s disease

    J. Szász, V. Constantin, K. Orban-Kiss, S. Bataga, L. Bancu, R. Neagoe, J. Szederjesi, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmari (TARGU MURES, Romania)

    Objective: To evaluate the profile of those patients with advanced Parkinson’s Disease (APD) in which we decided to use continuous 24-hour administration of Levodopa Carbidopa…
  • 2023 International Congress

    Plasma biomarkers in iRBD patients serve as potential markers of early PD and motor severity

    B. Huxford, C. Simonet-Hernandez, L. Pérez-Carbonell, A. Schrag, R. Dobson, A. Noyce (London, United Kingdom)

    Objective: We aimed  to investigate biomarkers of inflammation and neuroaxonal damage in people with isolated REM sleep behaviour disorder (iRBD) compared to controls, and understand…
  • 2023 International Congress

    A 10-year service evaluation of a Cervical Dystonia Botulinum Toxin A Clinic: Factors associated with a patient satisfaction.

    M. Bradley, M. Ryan, F. Molloy (Dublin, Ireland)

    Objective: To review the factors associated with patient satisfaction of routine care with BoNT-A injections for CD in a “real world” clinical setting. Background: Cervical…
  • 2023 International Congress

    Patients activation in people with Parkinson disease and its relation to personal factors

    B. Naamneh Abuelhija, M. Kafri, M. Kestenbaum, S. Giveon, G. Yogev-Seligmann (Haifa, Israel)

    Objective: To identify individual factors associated with patient activation among people with Parkinson’s disease (PD). Background: The concept of patient activation captures subjective aspects of…
  • 2023 International Congress

    Tremor in patients with chronic inflammatory demyelinating polyneuropathy: prevalence and severity

    G. Pallada, SEM. Ten Holter, F. Eftimov, RMA. de Bie, AF. van Rootselaar, JM. Dijk (Amsterdam, Netherlands)

    Objective: To determine prevalence and severity of tremor in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Background: Tremor is an underrecognized and possibly disabling symptom…
  • 2023 International Congress

    motor and non-motor correlates of hyposmia detected by the italian olfactory identification test (ioit) in an italian cohort of parkinson’s disease patients

    A. Mechelli, N. Tambasco, M. Filidei, C. Maremmani, M. Pierini, P. Nigro, S. Simoni, L. Parnetti (Catanzaro, Italy)

    Objective: To characterize olfaction in a cohort of PD patients and to investigate the relationship between olfactory impairment with both motor and non-motor features and other clinical characteristics…
  • 2023 International Congress

    Cortical excitability of sensorimotor cortex in Parkinson’s disease-related pain

    MK. Lu, CM. Chen, SM. Liu, CH. Tsai (Taichung, Taiwan)

    Objective: To clarify the functional role of sensorimotor cortex in Parkinson’s disease (PD)-related pain. Background: Pain is one of the most common nonmotor symptoms in…
  • 2023 International Congress

    Primary CNS Lymphoma presenting with Hemichorea Hemiballismus.

    N. Sharma (Chandigarh, India)

    Objective: Completing the list of Hemichorea Hemiballismus apart from stroke and hyperglycaemic states. Background: 61years old female presented with subacute onset abnormal irregular purposeless movements…
  • 2023 International Congress

    Lysosomal-driven reduction of alpha-synuclein aggregates in a neuron-like model of Parkinson’s disease

    S. Lucas-Del-Pozo, G. Uras, F. Fierli, AHV. Schapira (London, United Kingdom)

    Objective: To test whether PIKfyve inhibition results in a lysosomal-driven reduction of alpha-synuclein aggregates in a mutant neuroblastoma cell line overexpressing an aggregation-prone form of…
  • 2023 International Congress

    AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington’s disease minipigs up to 5 years

    L. Van_der Bent, C. Brouwers, A. Stam, L. Spronck, J. Klíma, J. Juhásová, B. Levinská, S. Juhás, J. Motlík, M. Evers, Z. Ellederova, A. Valles (Amsterdam, Netherlands)

    Objective: Our objective is to assess long-term safety of and durability of an adeno-associated viral vector serotype 5 encoding an engineered miRNA (AAV5-miHTT) targeting human…
  • « Previous Page
  • 1
  • …
  • 39
  • 40
  • 41
  • 42
  • 43
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley